Payment overview · 2025
General Payments
$1,580.24
96 reported records · 20 companies
Healthcare provider profile · identity verified
James Joseph Caserio, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · HENDERSONVILLE, NC · NPI 1558320945
Verified facts
What the public records show
CMS Open Payments records show James Joseph Caserio, M.D. received $1,580.24 in general payments during 2025 across 96 reported records.
ABBVIE INC. accounted for 32.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic, Rexulti, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Vraylar by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Rexulti by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 236 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $505.47 | 32.0% | 44 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $149.96 | 9.5% | 8 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $120.79 | 7.6% | 6 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $116.77 | 7.4% | 5 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $90.32 | 5.7% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $85.03 | 5.4% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $78.54 | 5.0% | 5 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $67.25 | 4.3% | 3 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $52.63 | 3.3% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $46.65 | 3.0% | 3 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $46.08 | 2.9% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $41.65 | 2.6% | 2 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $39.67 | 2.5% | 2 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $25.83 | 1.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $25.41 | 1.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $21.93 | 1.4% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.65 | 1.2% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $18.92 | 1.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.16 | 0.9% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $13.53 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,580.24 | 96 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $285.24 | 23 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $220.23 | 21 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $188.97 | 16 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $158.42 | 7 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $149.96 | 8 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $120.79 | 6 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $90.32 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $85.03 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $85.03 | 4 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $67.25 | 3 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $52.63 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $46.65 | 3 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $46.08 | 2 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $39.67 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $33.16 | 2 | 2025 |
Source payment records
|
|||||
| NEXIUM Normalized: nexium |
Drug | AstraZeneca Pharmaceuticals LP | $31.63 | 2 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $25.83 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $25.41 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $21.93 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $21.93 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $19.65 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $18.92 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.16 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.16 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $13.53 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 236 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 57 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 90 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
107 | 29 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
39 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
90 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
64 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
57 | 16 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
236 | 53 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
52 | 52 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Losartan Potassium | Losartan Potassium | 397 | 120 |
| Hydrochlorothiazide | Hydrochlorothiazide | 376 | 115 |
| Pantoprazole Sodium | Pantoprazole Sodium | 312 | 108 |
| Simvastatin | Simvastatin | 312 | 96 |
| Lorazepam | Lorazepam | 300 | 68 |
| Alprazolam | Alprazolam | 266 | 63 |
| Eliquis | Apixaban | 236 | 53 |
| Levothyroxine Sodium | Levothyroxine Sodium | 236 | 74 |
| Atorvastatin Calcium | Atorvastatin Calcium | 233 | 76 |
| Amlodipine Besylate | Amlodipine Besylate | 228 | 75 |
| Potassium Chloride | Potassium Chloride | 215 | 78 |
| Furosemide | Furosemide | 207 | 63 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 200 | 62 |
| Gabapentin | Gabapentin | 191 | 52 |
| Prednisone | Prednisone | 183 | 77 |
| Zolpidem Tartrate | Zolpidem Tartrate | 146 | 47 |
| Tamsulosin Hcl | Tamsulosin Hcl | 142 | 51 |
| Metformin Hcl | Metformin Hcl | 139 | 52 |
| Citalopram Hbr | Citalopram Hydrobromide | 130 | 45 |
| Azithromycin | Azithromycin | 128 | 92 |
| Oxycodone Hcl | Oxycodone Hcl | 125 | 19 |
| Celecoxib | Celecoxib | 120 | 43 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 120 | 40 |
| Lisinopril | Lisinopril | 119 | 39 |
| Omeprazole | Omeprazole | 116 | 41 |
| Metoprolol Succinate | Metoprolol Succinate | 114 | 38 |
| Trazodone Hcl | Trazodone Hcl | 114 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 111 | 43 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 108 | 36 |
| Synthroid | Levothyroxine Sodium | 107 | 29 |
| Diazepam | Diazepam | 104 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 96 | 38 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 90 | 25 |
| Tramadol Hcl | Tramadol Hcl | 89 | 22 |
| Clonidine Hcl | Clonidine Hcl | 87 | 35 |
| Xarelto | Rivaroxaban | 87 | 19 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 83 | 58 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 78 | 18 |
| Pregabalin | Pregabalin | 77 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 75 | 18 |
| Meloxicam | Meloxicam | 70 | 17 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 67 | 20 |
| Jardiance | Empagliflozin | 64 | 15 |
| Atenolol | Atenolol | 63 | 20 |
| Donepezil Hcl | Donepezil Hcl | 63 | 15 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 61 | 12 |
| Famotidine | Famotidine | 61 | 12 |
| Ozempic | Semaglutide | 57 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 56 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 55 | 20 |
| Allopurinol | Allopurinol | 54 | 17 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 54 | 40 |
| Paxlovid | Nirmatrelvir/Ritonavir | 52 | 52 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 51 | 16 |
| Ezetimibe | Ezetimibe | 51 | 20 |
| Fluconazole | Fluconazole | 51 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 51 | 16 |
| Levofloxacin | Levofloxacin | 51 | 38 |
| Memantine Hcl | Memantine Hcl | 51 | 11 |
| Levetiracetam | Levetiracetam | 50 | 11 |
| Sertraline Hcl | Sertraline Hcl | 50 | 16 |
| Bupropion Xl | Bupropion Hcl | 49 | 18 |
| Clonazepam | Clonazepam | 49 | 12 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 48 | 28 |
| Finasteride | Finasteride | 47 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 45 | suppressed |
| Entresto | Sacubitril/Valsartan | 44 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 44 | 31 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 43 | 12 |
| Colchicine | Colchicine | 41 | 18 |
| Montelukast Sodium | Montelukast Sodium | 40 | 12 |
| Farxiga | Dapagliflozin Propanediol | 39 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 39 | 12 |
| Benazepril Hcl | Benazepril Hcl | 38 | 12 |
| Ondansetron Odt | Ondansetron | 38 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 38 | 13 |
| Warfarin Sodium | Warfarin Sodium | 38 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 37 | suppressed |
| Spironolactone | Spironolactone | 37 | 13 |
| Myrbetriq | Mirabegron | 35 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 35 | suppressed |
| Januvia | Sitagliptin Phosphate | 34 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 34 | suppressed |
| Klor-Con M20 | Potassium Chloride | 33 | 11 |
| Xtampza Er | Oxycodone Myristate | 33 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 32 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 32 | 13 |
| Propranolol Hcl | Propranolol Hcl | 32 | suppressed |
| Mirtazapine | Mirtazapine | 31 | suppressed |
| Mounjaro | Tirzepatide | 30 | suppressed |
| Acyclovir | Acyclovir | 29 | 13 |
| Estradiol | Estradiol | 29 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 29 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 29 | 13 |
| Aripiprazole | Aripiprazole | 28 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 28 | 13 |
| Rexulti | Brexpiprazole | 27 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 19 |
| Digoxin | Digoxin | 26 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 25 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Latanoprost | Latanoprost | 25 | suppressed |
| Livalo | Pitavastatin Calcium | 25 | suppressed |
| Mesalamine | Mesalamine | 25 | suppressed |
| Metronidazole | Metronidazole | 25 | 14 |
| Raloxifene Hcl | Raloxifene Hcl | 25 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 24 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 23 | 11 |
| Carvedilol | Carvedilol | 22 | suppressed |
| Desoximetasone | Desoximetasone | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 17 |
| Methylprednisolone | Methylprednisolone | 22 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 22 | suppressed |
| Lamotrigine | Lamotrigine | 21 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 21 | suppressed |
| Dofetilide | Dofetilide | 20 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Vraylar | Cariprazine Hcl | 20 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 19 | suppressed |
| Gavilyte-G | Peg3350/Sod Sulf,bicarb,cl/Kcl | 18 | 18 |
| Amoxicillin | Amoxicillin | 17 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 17 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 17 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 17 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 16 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 16 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 15 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Dexamethasone | Dexamethasone | 14 | 12 |
| Nystatin | Nystatin | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Adderall Xr | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 13 | suppressed |
| Prolia | Denosumab | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Roflumilast | Roflumilast | 13 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Epinephrine | Epinephrine | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Invokana | Canagliflozin | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 12 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Buprenorphine | Buprenorphine | 11 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 11 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 11 | suppressed |
| Praluent Pen | Alirocumab | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
| Triazolam | Triazolam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,580.24 · 96 records | ABBVIE INC. | Auvelity, BREZTRI, CAPLYTA, ELIQUIS, FANAPT, JATENZO, Kerendia, LEQVIO, Leqembi, NEXIUM, NURTEC ODT, OTEZLA, Ohtuvayre, Omnipod, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, Tymlos, UBRELVY, VRAYLAR, XIFAXAN, ZEPBOUND | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error